tirzepatide news november 2025 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly September 2, 2025: U.S. compounding

Semaglutides Impact on Womens Weight Loss Women face unique challenges in weight management, from hormonal fluctuations to pregnancy and menopause, all of which can affect metabolism and weight

It can be managed by drinking plenty of water, eating small meals, and avoiding heavy or greasy foods that might trigger discomfort

Hence, semaglutide can provide dual benefit to patients with type 2 diabetes and obesity (diabesity)

This means broader access, more formulation options, and likely competitive pricing strategies designed to capture market share from existing GLP-1 agonists

After numerous reader requests, we conducted a side-by-side comparison of two industry giants SkinnyRx and WeightWatchers to deliver a clear recommendation for those seeking a reliable path to healthy weight loss

The study (PDF) was conducted by researchers from the University of British Columbia researchers, reviving some of the oldest concerns about Ozempic hair loss since the drug became the go-to treatment for obesity and weight loss in recent years